Recruiting
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation - CA246-0005
Updated: 18 June, 2024 | ClinicalTrials.gov
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Inclusion Criteria: - Histologically confirmed diagnosis of a solid tumor malignancy harboring KRAS G12D mutation in tumor tissue or ctDNA. - Unresectable or metastatic disease. - Patients must have received standard therapies appropriate for their tumor type and stage; first-line treatment for PDAC for certain cohorts. - Presence of tumor lesions to be evaluated per RECIST v1.1: 1. in the Phase 1 dose escalation cohorts, patients must have measurable or evaluable disease. 2. in the Phase 1b and Phase 2 cohorts, patients must have measurable disease. - Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. - Adequate organ function. - Age ≥ 18 years Exclusion Criteria: - Active brain metastases or carcinomatous meningitis. - Prior treatment with a KRAS G12D inhibitor (Phase 1b & Phase 2 only). - History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment. - History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow oral medications. - History of malignant small bowel obstruction. - Cardiac abnormalities.
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
